Determining whether the effect of liraglutide on non‐alcoholic fatty liver disease depends on reductions in the body mass index

BACKGROUND AND AIM: Non‐alcoholic fatty liver disease (NAFLD) initially presents as steatosis, which can progress to non‐alcoholic steatohepatitis (NASH), and often presents clinically alongside metabolic syndromes. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are regularly utilized to trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiomi, Megumi, Tanaka, Yoichi, Takada, Tesshu, Otori, Katsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578289/
https://www.ncbi.nlm.nih.gov/pubmed/33102775
http://dx.doi.org/10.1002/jgh3.12384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578289/
https://www.ncbi.nlm.nih.gov/pubmed/33102775
http://dx.doi.org/10.1002/jgh3.12384

Ejemplares similares